Calithera Biosciences (CALA) Reports Q3 Loss of $0.49/Share

Calithera Biosciences (NASDAQ: CALA) reported Q3 EPS of ($0.49), versus ($16.85) reported last year.

Anticipated Upcoming Milestones

• Hematologic Phase 1 clinical trial data by year end 2015
• Initiation of six CB-839 combination expansion cohorts by year end 2015
• CB-839 combination therapy data in mid-2016
• Filing of investigational new drug application (IND) for arginase inhibitor CB-1158 in the first half of 2016

Guidance:

Calithera is updating its guidance of its cash, cash equivalents and investments to be at least $70 million at the end of 2015, exclusive of any license milestone payments or funds arising from any additional new collaborations or partnerships, equity financings or other new sources.

For earnings history and earnings-related data on Calithera Biosciences (CALA) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance
• ZKH Group Limited (ZKH) Reports Q2 EPS of $0.04